Becker J C, Muller-Tidow C, Serve H, Domschke W, Pohle T
World J Gastroenterol. 2006 Jun 7;12(21):3297-305. doi: 10.3748/wjg.v12.i21.3297.
Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy. Only preliminary data exist, however, on the use of the currently clinically available drugs such as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, and imatinib in the setting of gastric cancer. Preclinical data suggest a potential benefit of their use, especially in combination with "conventional" cytostatic therapy. This review summarizes the current knowledge about their use in cancer therapy as well as new approaches and drugs to optimize treatment success.
受体酪氨酸激酶（RTK），如表皮生长因子受体家族，参与肿瘤形成的多个步骤，包括增殖和转移扩散。几种已知的RTK在胃癌中上调，是靶向治疗的主要靶点。然而，关于目前临床上可用的药物，如曲妥珠单抗、西妥昔单抗、贝伐单抗、吉非替尼、厄洛替尼和伊马替尼在胃癌治疗中的应用，仅有初步数据。临床前数据表明它们的使用可能有益，特别是与“传统”细胞抑制疗法联合使用时。本综述总结了目前关于它们在癌症治疗中的应用的知识，以及优化治疗效果的新方法和药物。
